| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3996976 | Practical Radiation Oncology | 2014 | 7 Pages |
Abstract
Timing of adjuvant CRT for resectable pancreatic cancer may not significantly affect LRC or OS. These findings support the ongoing RTOG 0848 trial design, and provide reassurance that delaying CRT until completion of chemotherapy should not significantly impact LRC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jennifer Y. MD, Stephanie K. MD, Jackie PhD, Harvey J. MD, PhD, David P. MD, Lawrence S. MD, Eunice L. MD, Cristina R. MD, Jill N. MD, Andrew X. MD, PhD, Brian M. MD, Jennifer A. MD, MPH, Thomas A. MD, Nadine J. MD, MPH, Carlos MD, Theodore S. MD,